Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca announced proposed board changes with Karen Knudsen, a recognized cancer scientist, being nominated as a Non-Executive Director at the upcoming AGM in April 2025. Knudsen, known for her work in oncology and healthcare innovation, is set to join the Science and Sustainability Committees. Concurrently, Deborah DiSanzo and Andreas Rummelt will retire from the board. These changes reflect AstraZeneca’s strategic focus on enhancing its expertise in science and sustainability, potentially influencing its industry positioning and operations.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in fields such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are distributed in over 125 countries and used by millions of patients worldwide.
YTD Price Performance: 11.85%
Average Trading Volume: 2,816,726
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £181.5B
Learn more about AZN stock on TipRanks’ Stock Analysis page.
